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parison with that from the environment and empha-
sised the capacity of the immune system to respond
effectively to numerous simultaneous antigens.8 Using
data linkage, Miller et al found no evidence for an
increase in admissions to hospital for serious bacterial
infections following MMR vaccination. 9
One disadvantage of giving vaccines in combina-
tion is that it may not always be clear which component
is responsible for a particular adverse event. As impor-
tant as safety is ensuring that combining antigens does
not compromise the protection afforded by each anti-
gen. In the study by Schmitt et al, no difference was
found in subjects achieving protective concentrations
of antibodies against diphtheria, tetanus, hepatitis B,
and polio.5 Concentrations of pertussis antibody were
the same for both groups and comparable with those
achieved in trials of DTaP alone. However, the concen-
trations of Hib polyribosylribitol phosphate (PRP)
antibody were statistically significantly lower in those
children receiving all the antigens mixed together. The
clinical significance of this is uncertain.
One of the longest established combination vaccines
is DTwP. Two Swedish vaccine trials found a significant
difference in post-immunisation levels of diphtheria
antitoxin depending on the presence and nature of any
pertussis antigens in the vaccine.10 The addition of an
efficacious wholecell pertussis (wP) component to diph-
theria and tetanus vaccine increased the geometrical
mean titre of diphtheria antitoxin in the recipients,
whereas the addition of acellular pertussis (aP) or a
poorly efficacious wholecell pertussis vaccine produced
lower concentrations than only diphtheria and tetanus
vaccine. In a few children, the concentrations reached
were considered non-protective, confirming the well
known adjuvant effect of efficacious wholecell pertussis
vaccines. DTwP vaccines can be combined with Hib vac-
cines with no clinically significant loss in immunogenic-
ity, but when DTaP is used instead lower concentrations
of Hib PRP antibodies have been observed,11 and in
some cases these are below protective levels. The clinical
significance of this was unclear.
However, there has been a rise in Hib cases in fully
immunised children in the United Kingdom. This is
probably in part due to the use of a combined
DTaP/Hib preparation.12 Dagan et al reported that
infants who were given a diphtheria-tetanus-pertussis-
polio-Hib vaccine, in which the Hib component was
conjugated to tetanus, simultaneously with a pneumo-
coccal vaccine also conjugated to tetanus toxoid had
lower Hib PRP antibody concentrations than infants
who had received pneumococcal vaccine conjugated to
diphtheria toxoid.13 Furthermore, children who had
received higher doses of pneumococcal tetanus conju-
gate had poorer responses. This implies that difficulties
may arise in using simultaneous or combined vaccines
that have conjugates in common.
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Management of bacterial meningitis in adults
Algorithm from the British Infection Society represents current standard of care
T
he treatment of bacterial meningitis represents
one of the success stories of modern medicine,
particularly antibiotics. In the pre-antibiotic era
bacterial meningitis was almost always fatal, but the
prompt use of appropriate antibiotics together with
supportive care can undoubtedly reduce the morbidity
and the mortality of this condition substantially. And
yet just 10 years ago a large study of acute bacterial
meningitis in adults found a mortality of 25%.1 Why
can’t we do better than that?
Acute bacterial meningitis tends to present to non-
specialist, and often inexperienced, junior doctors. It is
not very common—there are about 1000 patients in
the United Kingdom each year—and so individual doc-
tors will not see many patients. These are exactly the
circumstances in which a management algorithm can
help. The British Infection Society has recently
published such an algorithm for the initial manage-
ment of adult patients with presumed bacterial menin-
gitis,2 and which represents an updated version of the
evidence based recommendations published by the
society four years ago.3 Key to the success of algorithms
such as this one is simplicity. The new guidelines
recommend a third generation cephalosporin such as
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cefotaxime or ceftriaxone as the first line of treatment in
most patients, with the addition of ampicillin for older
patients (to cover the possibility of Listeria infection), and
vancomycin with or without rifampicin in case of a seri-
ous risk of infection due to penicillin resistant pneumo-
cocci. Importantly, the society recognises that a good
outcome depends on factors other than the choice of
antibiotic alone. Awareness of the early clinical signs,
and prompt attention to oxygen requirements and
circulatory support are rightly stressed.
Algorithms are not intended to cover all circum-
stances. For example, in some parts of the world pneu-
mococci remain predictably sensitive to penicillin, and
this drug can remain a first line agent for presumed
pneumococcal meningitis, but we do not know how
long this will be true. Patients in special or high risk
groups, such as immunocompromised people or small
children, present particular problems, and expert
advice needs to be sought immediately.
Some will argue with the detail. The authors state
that a lumbar puncture should not be done in patients
with septicaemic meningococcal disease and take a
relatively conservative approach to lumbar puncture
and the use of computed tomography scans in general.
The evidence base for these assertions is not always
clear. It needs to be acknowledged that because of a
lack of systematic controlled clinical trials, many of the
recommendations of the working party, including
those on the use of antibiotics, are based on expert
opinion and consensus driven guidelines rather than a
secure evidence base. However, in the absence of better
evidence most doctors accept that documents such as
this generally represent the standard of care for a par-
ticular clinical condition. The problem is that despite
this guidelines are often not followed. In a revealing
study carried out in the Netherlands, van de Beek et al
followed up 365 adult patients with bacterial meningi-
tis.4 A year before the study began, a multiprofessional
group of Dutch experts drew up guidelines for the
empirical treatment of bacterial meningitis. These were
agreed at a national consensus conference and were
subsequently widely disseminated throughout the
country. During their study, van de Beek et al found
that only a third of patients received treatment in com-
pliance with the guidelines. In patients over 60 years
and those with other risk factors who were arguably at
greater risk of a poor outcome if treatment was subop-
timal the compliance rate was as low as 17%.
Although de Beek et al could not show any obvious
clinical detriment as a result of failure to comply with
the approved regimen there are important lessons
here. Clearly, there are many reasons why the uptake of
such guidelines may be low. These include poor quality
advice (for example, not evidence based or not practi-
cal), and poor dissemination of the information
(targeting the wrong group of doctors, for example).
Guidelines for the use of antibiotics are becoming
increasingly popular as a means of improving the
quality of care, but if they are to be effective they need
careful consideration—not just of their content, but of
how they are followed up and implemented.5
An additional but less obvious benefit of the
publication of such guidelines is that they draw attention
to changing practice in a rapidly moving field. At the
time of the last leading article in the BMJ dealing with
acute bacterial meningitis, just three years ago,6 the
management of penicillin-resistant pneumococcal infec-
tion was unclear and the role of corticosteroids debated.
In the current recommendations from the society a
combination of vancomycin and rifampicin is advised if
resistance to penicillin is considered likely. Notably the
use of adjunctive corticosteroids has changed after the
recent publication of the European dexamethasone
meningitis study, which showed a significant reduction
in mortality in patients who were given dexamethasone
10 mg every six hours for four days and started just
before or at the same time as the first dose of antibiotics.7
However, though bacterial meningitis is a seemingly
tractable infection, in this study the mortality from
pneumococcal meningitis was still 14%, even in the
group treated with steroids. There is still much to do.
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No-fault compensation systems
Experience elsewhere suggests it is time for the UK to introduce a pilot scheme
I
n 1978 the Pearson Commission in the United
Kingdom rejected a no-fault system in dealing
with clinical negligence. While declaring the exist-
ing tort system as costly, cumbersome, prone to delay,
and too capricious in its operation to be defensible, the
commission rejected no-fault compensation on
grounds of the difficulty in overhauling the tort liability
system and the perceived difficulties in causation judg-
ments.1 A general conservatism in the legal profession
and opposition from the insurance industry were other
factors. Much has changed in the NHS since then.
The long overdue white paper on the reform of the
clinical negligence compensation system is much
awaited. Reforms to be considered include fixed tariffs
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